Resolution Therapeutics advanced both its clinical and corporate profile this week as it progresses RTX001, a first-in-class regenerative macrophage therapy for end-stage liver disease. The company confirmed that the interim analysis cohort in its Phase I/II EMERALD trial is now fully recruited across 15 sites in the U.K. and Spain, with an interim data readout targeted for the end of Q3 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Management used the Advanced Therapies Congress in London to underscore Resolution’s positioning in regenerative macrophage therapy for inflammatory and fibrotic diseases. Multiple talks and posters centered on RTX001 drew what the company described as strong interest from conference attendees, reinforcing internal conviction in the program and its upcoming EMERALD milestone.
To support execution, Resolution appointed Louise Rowe as Vice President of Operations, bringing more than 30 years of drug development and commercialization experience in cell and gene therapies. Her track record includes leading Libmeldy to European marketing authorization at Orchard Therapeutics and helping advance AVB 101 at AviadoBio through IND clearance and FDA Fast Track designation.
The EMERALD program and RTX001 also received industry recognition, winning the “Best Therapeutic R&D Programme of the Year” award at the 2026 One Nucleus Awards, boosting sector visibility even as clinical risks remain unchanged. The company further expanded its presence through a BioCentury feature, a Drug Discovery World podcast, and briefings with U.K. health policymakers at Edinburgh BioQuarter.
Resolution highlighted its focus on standardized, accessible, and commercially sustainable cell and gene therapies, including CMC, AI- and automation-enabled manufacturing, and supply chain capabilities. This early attention to scalability and payer expectations may support future commercialization efforts if RTX001 proves safe and effective.
In intellectual property, VP of IP & Technology Strategy Eli Gilsohn was named to World Intellectual Property Review’s Global In-House Elite 2026 list, underscoring the company’s emphasis on protecting its global IP portfolio. Overall, the week reflected solid clinical progress, leadership strengthening, and growing external recognition ahead of the key EMERALD interim readout.